Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PER2 | O15055 | 2/20 | 0.39 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446480 | 0.89 | PRKAB2 (0.39) | KDM4EALDH1A1PRMT5WDR77POLB | |
| SCHEMBL8741576 | 0.83 | — | — | |
| SCHEMBL1446194 | 0.82 | PRMT5 (0.38) | KDM4EPRMT5WDR77POLBGAA | |
| SCHEMBL1446411 | 0.80 | PRMT5 (0.37) | PRMT5WDR77POLBGAASMN1; SMN2 | |
| SCHEMBL31126065 | 0.80 | POLB (0.40) | KDM4EPRMT5WDR77POLBGAA | |
| SCHEMBL24802723 | 0.80 | PRMT5 (0.37) | PRMT5WDR77POLBGAASMN1; SMN2 | |
| SCHEMBL4035338 | 0.80 | PRMT5 (0.37) | PRMT5WDR77POLBGAASMN1; SMN2 | |
| SCHEMBL6893925 | 0.80 | PER2 (0.37) | KDM4EALDH1A1PRMT5WDR77POLB | |
| SCHEMBL21329587 | 0.80 | F10 (0.37) | PRMT5WDR77POLBGAASMN1; SMN2 | |
| SCHEMBL15110556 | 0.79 | GLA (0.50) | KDM4EALDH1A1PRMT5WDR77POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558953-B1 | METHOD FOR THE MANUFACTURING OF 2-(3-(ALKYL AND ALKENYL)MORPHOLINO)-ETHAN-1-OLS | LUNDBECK PHARMACEUTICALS ITALY S P A (IT) | 2021-05-19 | — | — | EP | claimed |
| US-10717747-B2 | Method for the manufacturing of 2-(3-(alkyl and alkenyl)morpholino)-ethan-1-ols | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2020-07-21 | — | — | US | claimed |
| EP-3558953-A1 | METHOD FOR THE MANUFACTURING OF 2-(3-(ALKYL AND ALKENYL)MORPHOLINO)-ETHAN-1-OLS | Lundbeck Pharmaceuticals Italy S.p.A. (IT) | 2019-10-30 | — | — | EP | claimed |
| WO-2018115111-A1 | METHOD FOR THE MANUFACTURING OF 2-(3-(ALKYL AND ALKENYL)MORPHOLINO)-ETHAN-1-OLS | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2018-06-28 | — | — | WO | claimed |
| EP-1492536-B1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-09 | — | — | EP | claimed |
| US-7119084-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-10 | — | — | US | claimed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | claimed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4230264-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2026-01-28 | — | — | EP | disclosed |
| US-20250299695-A1 | FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM | RESONAC CORPORATION (JP) | 2025-09-25 | — | — | US | disclosed |
| WO-1998013354-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| US-5559256-A | Aminediol protease inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0580402-A2 | Aminediol protease inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-01-26 | — | — | EP | disclosed |
| US-4009195-A | FROM 1-ALKENES AND ACRYLIC ACID DERIVATIVES | ROHM AND HAAS COMPANY (US) | 1977-02-22 | — | — | US | disclosed |
| US-3994958-A | OF 1-ALKENES AND ACRYLIC ACID DERIVATIVES | ROHM AND HAAS COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
| US-3968148-A | Copolymers of 1-alkenes and acrylic acid derivatives | ROHM AND HAAS COMPANY (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717747-B2 | Method for the manufacturing of 2-(3-(alkyl and alkenyl)morpholino)-ethan-1-ols | THOP1, MDN1, CYP8B1 | KDM4E 1458/4885ALDH1A1 891/4885PRMT5 2119/4885 |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNNA1, CTNND1 | KDM4E 3019/4885ALDH1A1 1195/4885PRMT5 2490/4885 |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | KDM4E 3938/4885ALDH1A1 1002/4885PRMT5 1362/4885 |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | KDM4E 4252/4885ALDH1A1 731/4885PRMT5 2826/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | KDM4E 3441/4885ALDH1A1 1208/4885PRMT5 1125/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | KDM4E 3950/4885ALDH1A1 1933/4885PRMT5 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.